B-Cell Lymphomas constitute 90+% of all lymphomas, and their treatment has progressed beyond the classic CHOP regimen. T-Cell Lymphomas, on the other hand, are often treated with CHOP, as there remains no standard treatment for them. Results with CHOP are far less than optimum. Even today, a relapsed or chemo-refractory state is required to trigger the availability of newer targeted therapies - but such a condition places the patient in a much higher risk category with considerably poorer outcomes. However, new strategies are being developed and this paper details some of the research.


A review of the article, by various T-Cell Lymphoma luminaries, is here: